Why the Adderall Shortage Keeps Coming Back Despite Quota Hikes

Type "Adderall shortage" into the FDA's own drug-shortage database today, Oct. 1, 2026, and the page still returns the same blunt line it has carried, on and off, since October 2022: amphetamine mixed salts, "Currently in Shortage." Four years, three rounds of federal production-quota increases and dozens of manufacturer notices later, the flag hasn't come down.

That persistence confuses a lot of patients, because the fix sounds simple on paper. The Drug Enforcement Administration sets a national ceiling, called an Aggregate Production Quota, on how much amphetamine, methylphenidate and related stimulants U.S. manufacturers may produce each year. Raise the ceiling, the logic goes, and more pills should follow. The DEA has in fact raised it more than once since 2023. The shortage has outlasted every increase, and the reason has less to do with the headline number than with what happens to it afterward.

How Washington caps a stimulant before it's manufactured

Amphetamine, dextroamphetamine and methylphenidate are Schedule II controlled substances under the Controlled Substances Act, the same legal category as fentanyl and oxycodone. For any Schedule II drug, the DEA, not the market, decides the total amount of active ingredient that can legally be produced in the United States in a given calendar year. That figure is the Aggregate Production Quota, published every January in the Federal Register for the year already underway, after a proposal and public comment period the previous fall.

The aggregate number is not handed out automatically. Individual manufacturers have to apply for their own slice of it using DEA forms with their own deadlines: a manufacturing-quota application each spring, plus a separate procurement quota covering the raw controlled-substance material a company needs on hand, according to the DEA's Diversion Control Division. The agency weighs those requests against expected medical need, export demand, and each company's recent sales and inventory, using data it gets partly from the FDA, which tracks prescribing trends and collects shortage reports directly from drugmakers.

So a January headline announcing higher 2026 quotas describes only the size of the pie. Who gets a slice, and when, is a separate and much slower process that plays out company by company over the following months.

The same split between federal agencies, one counting grams and another counting pharmacy shelves, shows up elsewhere in the American drug market, from how compounding pharmacies fill gaps to why prescription-drug ads run on U.S. television.

Why a bigger ceiling doesn't refill the shelf

That gap between the national number and the pharmacy counter is where the shortage actually lives, according to health-policy researchers who have examined the quota system. A single national increase has to cascade through roughly 4,000 individual quota decisions a year, one for nearly every manufacturer, every drug code, every dosage form, before it turns into finished bottles, an analysis published by the Brookings Institution found.

Two features of the system slow that cascade even when the ceiling itself looks generous. DEA caps how much raw controlled-substance material a manufacturer can hold in inventory, sized to that company's recent sales. The rule is meant to prevent hoarding or diversion, but it also stops a company from stockpiling the input it would need to ramp up output quickly, the Brookings analysis noted. And when one manufacturer can't use its allocation, whether because of a contamination event, an active-ingredient shortfall or its own decision to deprioritize a low-margin generic, that unused quota doesn't automatically move to a competitor who could use it. DEA has generally treated a company's silence as a reason to wait for that firm to formally give the quota back rather than reassign it right away.

"Production limit on the drug's active ingredient is one of the main drivers for our inability to fully supply the market."

Apotex, a generic drugmaker, speaking to CBS News in 2024

Regulators and manufacturers have traded versions of that argument publicly for two years. DEA has maintained its aggregate limits are sufficient to cover legitimate medical need. Generic manufacturers counter that the quota each of them is individually granted, plus restrictions on how much raw ingredient they're allowed to hold, caps their output well before the industry as a whole reaches any national ceiling.

What's actually different about the 2026 cycle

Going into this year, DEA's own proposal was cautious. In a notice published Nov. 28, 2025, the agency proposed holding the base amphetamine and methylphenidate quotas essentially flat at 2025 levels, even while acknowledging that "in 2025, dosage form manufacturers reported shortages of specific ADHD medications" to the FDA, citing rising demand, supply-chain trouble, manufacturing and quality problems, active-ingredient shortfalls and manufacturers' own business decisions. DEA's own data showed domestic medical use of these stimulants had grown by an average of 6.74% in 2024 over 2023, driven largely by ADHD treatment.

That proposal drew 5,044 comments, an unusually large response for a routine annual quota notice. When the DEA published its final 2026 order on Jan. 5, 2026, several quotas came in higher than what the agency had proposed months earlier. Lisdexamfetamine, the active ingredient in Vyvanse, got the largest increase, rising to 51.29 million grams for the year to cover what the agency projected as continued double-digit growth in prescribing and exports. The base amphetamine and methylphenidate categories moved up only modestly by comparison.

DEA Assistant Administrator Cheri Oz framed the move as routine coordination rather than a course correction. DEA is committed to ensuring that patients can access the prescription medications that they need to stay healthy, she said in the agency's announcement, adding that supply disruptions can stem from manufacturing problems and distribution issues the agency doesn't control.

None of that changes the more basic pattern. DEA raised its ceiling in 2023, again in 2024 and again for 2026, and amphetamine mixed salts have remained on the FDA's shortage list through every one of those increases. A quota is a ceiling, not a guarantee. It caps how much manufacturers may legally make; it can't force a company through a contamination event, an ingredient bottleneck or a low-margin generic it has quietly decided not to keep making.

What this means for someone waiting on a refill

For a patient standing at the pharmacy counter this month, the honest answer is a modest one. A higher national quota is a necessary condition for the shortage to end, but not a sufficient one, and it takes months rather than days to show up as filled bottles because it depends on individual manufacturers actually using the share they're given. Pharmacists have more room than most patients realize to substitute an equivalent strength or a different manufacturer's version of the same generic without a new prescription. Switching brands or formulations for supply reasons is common practice, not a sign that something is wrong with the medication itself.

Manufacturers are already filing applications for their 2027 individual allocations this spring, under the same layered process that has shaped every cycle since the shortage began. Whether that produces a cleaner shelf next year depends less on what number the DEA prints in January than on whether the two dozen or so companies actually making these pills can get the raw ingredient, the manufacturing capacity and the business case to use the quota they're handed.